Chemical Modifications of siRNA for Increased Stability in Rat In Vivo Applications

Small interfering RNA (siRNA) is a powerful tool for gene silencing in vivo, but its therapeutic application in rat models is limited by rapid degradation by nucleases, poor cellular uptake, and potential immunogenicity. Chemical modifications of siRNA molecules have been developed to address these challenges by enhancing stability, reducing off-target effects, and improving pharmacokinetics while preserving gene silencing activity.

One of the most common modifications is 2′-O-methylation of the ribose sugar, which protects siRNA strands from exonuclease and endonuclease cleavage without significantly impairing incorporation into the RNA-induced silencing complex (RISC). Phosphorothioate backbone modifications replace a non-bridging oxygen with sulfur, increasing resistance to nuclease degradation and improving plasma half-life. However, excessive phosphorothioate content can increase toxicity and reduce RNAi potency, so modification patterns must be carefully balanced.

Another strategy involves incorporation of locked nucleic acids (LNAs) or constrained ethyl (cEt) modifications that rigidify the ribose ring and enhance binding affinity to target mRNA. LNAs increase thermal stability of siRNA duplexes and improve specificity, minimizing off-target gene silencing. However, their use requires precise placement to avoid compromising RISC loading. Incorporation of 2′-fluoro nucleotides also enhances nuclease resistance and affinity without significantly increasing immunogenicity.

Terminal modifications such as conjugation to cholesterol, GalNAc, or polyethylene glycol (PEG) moieties facilitate cellular uptake and tissue-specific targeting. For example, GalNAc conjugation enables receptor-mediated delivery to hepatocytes in rat liver models via asialoglycoprotein receptor binding. These conjugates also reduce renal clearance and improve pharmacodynamics.

Chemical modifications must preserve the siRNA’s ability to trigger efficient mRNA cleavage while minimizing activation of innate immune receptors such as Toll-like receptor 7 and 8, which recognize RNA patterns and induce inflammatory responses. Systematic evaluation of cytokine induction and immune cell activation in rat models is necessary to ensure biocompatibility.

In vivo, modified siRNAs are administered via intravenous, subcutaneous, or local injection depending on the target tissue. Biodistribution and knockdown efficiency are evaluated using qPCR, Western blot, and histology. Toxicity is assessed through liver enzyme levels, renal function markers, and histopathology.

In summary, strategic chemical modifications of siRNA enhance stability, delivery, and safety in rat in vivo models, enabling more effective gene silencing for both basic research and therapeutic development. Careful design and rigorous validation are critical to balancing efficacy with minimal adverse effects.